<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-GB>

<div class=WordSection1>

<h1><span lang=EN-US style='font-size:15.0pt;line-height:107%'>2008B07 List the
agents used therapeutically to reduce platelet function. Outline their
mechanisms of action, adverse effects, mode of elimination and duration of
action.</span></h1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>*Note increased bleeding risk is a potential side effect of all*</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>&nbsp;</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><b><span lang=EN-US>Pharmacodynamics:</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Mechanism of action (MoA)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Side effects (SE)</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><b><span lang=EN-US>Pharmacokinetics</span></b><u><span lang=EN-US>:</span></u></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Metabolism (M)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Excretion (E)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Duration (D)</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Aspirin (irreversible)</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: Irreversible COX1&amp;2 acetylation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>&#8595;TXA<sub>2</sub> production in platelet</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>Minimal effect on endothelial PGI<sub>2</sub> at low dose</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: bleeding peptic ulcer, nausea, Reye’s syndrome, toxicity -&gt;
  metabolic acidosis</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: 80% (liver)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: 20% (kidney)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: 7 days (new platelets)</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Dipyridamole</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: PDE inhibition -&gt; &#8593;cAMP</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: potentiate PGI<sub>2</sub></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SEs: bleeding headache, hypotension</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: live</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: bile</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: t<sub>1/2</sub></span><sub><span lang=EN-US>&#946;</span></sub><span
  lang=EN-US> 10 hours -&gt; BD dose</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Clopidogrel</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>Prodrug with active thiol metabolite</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: irreversible P2Y<sub>12</sub> ADP receptor antagonist (ADPRA)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: bleeding, risk of failure (2C19 polymorphism)</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: 50% (2C19)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: 50% (renal)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: 7 days</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Ticlopidine</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>Prodrug</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: irreversible P2Y<sub>12</sub> ADPRA</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: bleeding, TTP</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: liver</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: urine &gt; bile</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: 7 days</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Ticagrelor</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: Reversible P2Y<sub>12</sub> ADPRA</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>Has an equipotent metabolite</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: bleeding, dyspnoea (esp if asthma)</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: hepatic CYP3A4, 3A5</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: bile &gt; urine</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: 2 days</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Abciximab</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: GPIIbIIIa mAb antagonist</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: bleeding, &#8595;plt</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M&amp;E: reticulo-endothelial system</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: 2 days (prolonged binding)</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Tirofiban</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: GPIIbIIIa inhibitor</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: bleeding, &#8595;plt</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: nil</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: 66% urine, 33% bile</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: 8 hours</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Prostacyclin</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: G<sub>s</sub> GPCR -&gt; &#8593;cAMP -&gt; inhibit activation</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: liver, kidney, lung</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>D: very short (t<sub>1/2</sub></span><sub><span lang=EN-US>&#946;</span></sub><span
  lang=EN-US> 6 minutes)</span></p>
  </td>
 </tr>
 <tr>
  <td width=87 valign=top style='width:65.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Dextrans</span></p>
  </td>
  <td width=266 valign=top style='width:199.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>MoA: &#8595;von Willebrand factor</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>SE: anaphylaxis, impair blood cross matching</span></p>
  </td>
  <td width=247 valign=top style='width:185.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>M: nil?</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>E: renal</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:5.5pt;margin-bottom:.0001pt;text-indent:-5.5pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·</span><span
  lang=EN-US>Duration: 6-8 hours for volume expansion, ? antiplatelet duration</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
